acalabrutinib
astrazeneca
['calquence', 'cll']
calquence-containing treatment regimens produce more favorable results in both progression-free survival and overall response rate at five years, for patients with cll, #asco22 research presented by dr. sharman from showed. 
Cancer updates, research and education for patients with cancer, survivors and their caregivers to become empowered advocates in their journey.